Rhythm Pharmaceuticals Reports 47% Revenue Growth to $71.3 Million in Q2 2026

Rhythm Pharmaceuticals, Inc. reported significant financial results for the second quarter of 2026, with total revenues reaching $71.3 million, a 47% increase from $48.5 million in the same period last year. This growth was primarily driven by a higher volume of product sales, particularly for its lead product, IMCIVREE (setmelanotide), which is designed to treat rare neuroendocrine diseases. The company’s net loss for the quarter was $49.3 million, compared to a loss of $46.6 million in the prior year, reflecting ongoing investments in research and development as well as increased selling, general, and administrative expenses.

For the first half of 2026, Rhythm Pharmaceuticals reported total revenues of $131.4 million, up 62% from $81.2 million in the first half of 2025. The increase in revenue was attributed to a 52% rise in product revenue, which amounted to $131.4 million, while the company recognized a reduction in license revenue due to the termination of a previous agreement. The cost of sales also increased significantly, rising 75% to $16.1 million, driven by higher product costs associated with increased sales volume.

Operationally, the company has expanded its patient base, with over 400 patient start forms received for IMCIVREE for acquired hypothalamic obesity from approximately 300 prescribers as of June 30, 2026. The number of patients on reimbursed therapy globally increased by more than 20% compared to the first quarter of 2026. The company has achieved market access for IMCIVREE in over 25 countries outside the United States and continues to pursue additional markets. As of June 30, 2026, Rhythm Pharmaceuticals had approximately 330.9 million in cash and cash equivalents, which management believes will be sufficient to fund operations for at least the next 24 months.

In terms of strategic developments, Rhythm Pharmaceuticals has made significant progress in its clinical programs, including the successful completion of a pivotal Phase 3 trial for IMCIVREE in patients with acquired hypothalamic obesity. The company is also advancing its next-generation MC4R agonists, including RM-718 and bivamelagon, with ongoing clinical trials. The company anticipates launching IMCIVREE for acquired hypothalamic obesity in Japan by the end of 2026, pending regulatory approval.

Looking ahead, Rhythm Pharmaceuticals expects to continue incurring significant expenses and operating losses as it invests in the commercialization of IMCIVREE and the development of its pipeline. The company is focused on expanding its market presence and enhancing its product offerings while navigating the challenges of funding and operational scaling in the biopharmaceutical industry.